Влияние концентратов фибриногена, фактора XIII и активируемого тромбином ингибитора фибринолиза на плотность и фибринолитическую устойчивость кровяного сгустка в модели гиперфибринолиза
Ключевые слова:
фибриноген; фактор XIII; активируемый тромбином ингибитор фибринолиза; гиперфибринолиз.
Аннотация
Цель исследования — изучение возможности коррекции формирования кровяного сгустка и его фибринолитической устойчивости с помощью концентратов фибриногена, фактора XIII и активируемого тромбином ингибитора фибринолиза (TAFI) в модели гиперфибринолиза in vitro. Методика. В образцы цитратной крови, полученной от 24 взрослых здоровых добровольцев, добавляли концентрат фибриногена, фактора XIII и/или TAFI. Фибринолиз индуцировали добавлением тканевого активатора плазминогена. Свертывание крови индуцировали рекальцификацией и добавлением препарата тканевого фактора. Формирование и лизис сгустка изучали методом ротационной тромбоэластометрии. Результаты. Индукция фибринолиза не влияла на время свертывания и скорость формирования сгустка, но значительно уменьшала максимальную плотность сгустка и вызывала его лизис. Концентрат фибриногена замедлял скорость лизиса сгустка; концентрат фактора XIII усиливал механическую прочность сгустка и замедлял скорость его лизиса, не влияя при этом на время начала лизиса; TAFI усиливал механическую прочность и значительно отдалял время начала лизиса, оказывая тем самым наибольший корригирующий эффект. Заключение. Полученные данные демонстрируют потенциальную возможность коррекции гемостатического потенциала крови при гиперфибринолизе с помощью концентратов фибриногена, фактора XIII и TAFI, которые могут стать альтернативой традиционным антифибринолитикам.
Скачивания
Данные скачивания пока недоступны.
Литература
1. Veigas P. V., Callum J., Rizoli S., Nascimento B., da Luz L.T. A systematic review on the rotational thrombelastometry (ROTEM®) values for the diagnosis of coagulopathy, prediction and guidance of blood transfusion and prediction of mortality in trauma patients. Scand J Trauma Resusc Emerg Med. 2016; 24(1): 114.
2. Davenport R.A., Guerreiro M., Frith D., Rourke C., Platton S., Cohen M., et al. Activated protein C drives the hyperfibrinolysis of acute traumatic coagulopathy. Anesthesiology. 2017; 126(1): 115-27.
3. Ranucci M. Hemostatic and thrombotic issues in cardiac surgery. Semin Thromb Hemost. 2015; 41(1): 84-90.
4. Wada T., Gando S., Ono Y., Maekawa K., Katabami K., Hayakawa M., et al. Disseminated intravascular coagulation with the fibrinolytic phenotype predicts the outcome of patients with out-of-hospital cardiac arrest. Thromb J. 2016; 14: 43.
5. Ferro D., Celestini A., Violi F. Hyperfibrinolysis in Liver Disease. Clin Liver Dis. 2009; 13(1): 21-31.
6. Henry D.A., Carless P.A., Moxey A.J., O’Connell D., Stokes B.J., Fergusson D.A., et al. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev. 2011; (3):CD001886.
7. Wu Q., Zhang H.-A., Liu S.-L., Meng T., Zhou X., Wang P. Is tranexamic acid clinically effective and safe to prevent blood loss in total knee arthroplasty? A meta-analysis of 34 randomized controlled trials. Eur J Orthop Surg Traumatol. 2015; 25(3): 525-41.
8. Roberts I., Edwards P., Prieto D., Joshi M., Mahmood A., Ker K., et al. Tranexamic acid in bleeding trauma patients: an exploration of benefits and harms. Trials. 2017; 18(1): 48.
9. Godier A., Hunt B.J. Aprotinin as an alternative to tranexamic acid in cardiac surgery — Is this where we started from? Anaesth Crit Care Pain Med. 2017; 36(2): 79-81.
10. European Society of Anaesthesiology task force reports on place of aprotinin in clinical anaesthesia. Aprotinin: is it time to reconsider? Eur J Anaesthesiol. 2015;32(9):591-5.
11. Upadhyay S.P., Mallick P.N., Jagia M., Singh R.K.A. Acute arterial thrombosis associated with inadvertent high dose of tranexamic acid. Indian J Crit Care Med. 2013; 17(4): 237-9.
12. Silva M.M.C.G., Thelwell C., Williams S.C., Longstaff C. Regulation of fibrinolysis by C-terminal lysines operates through plasminogen and plasmin but not tissue-type plasminogen activator. J Thromb Haemost. 2012; 10(11): 2354-60.
13. Hijazi N., Abu Fanne R., Abramovitch R., Yarovoi S., Higazi M., Abdeen S., et al. Endogenous plasminogen activators mediate progressive intracerebral hemorrhage after traumatic brain injury in mice. Blood. 2015; 125(16): 2558-67.
14. Myles P.S., Smith J.A., Forbes A., Silbert B., Jayarajah M., Painter T., et al. Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery. N Engl J Med. 2017; 376(2): 136-48.
15. Sharma V., Katznelson R., Jerath A., Garrido-Olivares L., Carroll J., Rao V., et al. The association between tranexamic acid and convulsive seizures after cardiac surgery: a multivariate analysis in 11 529 patients. Anaesthesia. 2014; 69(2): 124-30.
16. Bucay I., O’Brien E.T., Wulfe S.D., Superfine R., Wolberg A.S., Falvo M.R., et al. Physical determinants of fibrinolysis in single fibrin fibers. PloS One. 2015; 10(2):e0116350.
17. Weisel J.W., Litvinov R.I. Fibrin Formation, Structure and Properties. Subcell Biochem. 2017; 82: 405-56.
18. Godier A., Parmar K., Manandhar K., Hunt B.J. An in vitro study of the effects of t-PA and tranexamic acid on whole blood coagulation and fibrinolysis. J Clin Pathol. 2017; 70(2): 154-61.
19. Hur W.S., Mazinani N., Lu X.J.D., Britton H.M., Byrnes J.R., Wolberg A.S. et al. Coagulation factor XIIIa is inactivated by plasmin. Blood. 2015; 126(20): 2329-37.
20. Kim P.Y., Stewart R.J., Lipson S.M., Nesheim M.E. The relative kinetics of clotting and lysis provide a biochemical rationale for the correlation between elevated fibrinogen and cardiovascular disease. J Thromb Haemost. 2007; 5(6): 1250-6.
21. Sabate A., Gutierrez R., Beltran J., Mellado P., Blasi A., Acosta F. et al. Impact of Preemptive Fibrinogen Concentrate on Transfusion Requirements in Liver Transplantation: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. Am J Transplant. 2016; 16(8): 2421-9.
22. Hethershaw E.L., Cilia La Corte A.L., Duval C., Ali M., Grant P.J., Ariеns R.A.S. et al. The effect of blood coagulation factor XIII on fibrin clot structure and fibrinolysis. J Thromb Haemost. 2014; 12(2): 197-205.
23. Rijken D.C., Abdul S., Malfliet J.J.M.C., Leebeek F.W.G., Uitte de Willige S. Compaction of fibrin clots reveals the antifibrinolytic effect of factor XIII. J Thromb Haemost. 2016; 14(7): 1453-61.
24. Ichinose A., Japanese Collaborative Research Group on AH13. Autoimmune acquired factor XIII deficiency due to anti-factor XIII/13 antibodies: A summary of 93 patients. Blood Rev. 2017; 31(1): 37-45.
25. Marar T.T., Boffa M.B. Identification of a thrombomodulin interaction site on thrombin-activatable fibrinolysis inhibitor that mediates accelerated activation by thrombin. J Thromb Haemost. 2016; 14(4): 772-83.
2. Davenport R.A., Guerreiro M., Frith D., Rourke C., Platton S., Cohen M., et al. Activated protein C drives the hyperfibrinolysis of acute traumatic coagulopathy. Anesthesiology. 2017; 126(1): 115-27.
3. Ranucci M. Hemostatic and thrombotic issues in cardiac surgery. Semin Thromb Hemost. 2015; 41(1): 84-90.
4. Wada T., Gando S., Ono Y., Maekawa K., Katabami K., Hayakawa M., et al. Disseminated intravascular coagulation with the fibrinolytic phenotype predicts the outcome of patients with out-of-hospital cardiac arrest. Thromb J. 2016; 14: 43.
5. Ferro D., Celestini A., Violi F. Hyperfibrinolysis in Liver Disease. Clin Liver Dis. 2009; 13(1): 21-31.
6. Henry D.A., Carless P.A., Moxey A.J., O’Connell D., Stokes B.J., Fergusson D.A., et al. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev. 2011; (3):CD001886.
7. Wu Q., Zhang H.-A., Liu S.-L., Meng T., Zhou X., Wang P. Is tranexamic acid clinically effective and safe to prevent blood loss in total knee arthroplasty? A meta-analysis of 34 randomized controlled trials. Eur J Orthop Surg Traumatol. 2015; 25(3): 525-41.
8. Roberts I., Edwards P., Prieto D., Joshi M., Mahmood A., Ker K., et al. Tranexamic acid in bleeding trauma patients: an exploration of benefits and harms. Trials. 2017; 18(1): 48.
9. Godier A., Hunt B.J. Aprotinin as an alternative to tranexamic acid in cardiac surgery — Is this where we started from? Anaesth Crit Care Pain Med. 2017; 36(2): 79-81.
10. European Society of Anaesthesiology task force reports on place of aprotinin in clinical anaesthesia. Aprotinin: is it time to reconsider? Eur J Anaesthesiol. 2015;32(9):591-5.
11. Upadhyay S.P., Mallick P.N., Jagia M., Singh R.K.A. Acute arterial thrombosis associated with inadvertent high dose of tranexamic acid. Indian J Crit Care Med. 2013; 17(4): 237-9.
12. Silva M.M.C.G., Thelwell C., Williams S.C., Longstaff C. Regulation of fibrinolysis by C-terminal lysines operates through plasminogen and plasmin but not tissue-type plasminogen activator. J Thromb Haemost. 2012; 10(11): 2354-60.
13. Hijazi N., Abu Fanne R., Abramovitch R., Yarovoi S., Higazi M., Abdeen S., et al. Endogenous plasminogen activators mediate progressive intracerebral hemorrhage after traumatic brain injury in mice. Blood. 2015; 125(16): 2558-67.
14. Myles P.S., Smith J.A., Forbes A., Silbert B., Jayarajah M., Painter T., et al. Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery. N Engl J Med. 2017; 376(2): 136-48.
15. Sharma V., Katznelson R., Jerath A., Garrido-Olivares L., Carroll J., Rao V., et al. The association between tranexamic acid and convulsive seizures after cardiac surgery: a multivariate analysis in 11 529 patients. Anaesthesia. 2014; 69(2): 124-30.
16. Bucay I., O’Brien E.T., Wulfe S.D., Superfine R., Wolberg A.S., Falvo M.R., et al. Physical determinants of fibrinolysis in single fibrin fibers. PloS One. 2015; 10(2):e0116350.
17. Weisel J.W., Litvinov R.I. Fibrin Formation, Structure and Properties. Subcell Biochem. 2017; 82: 405-56.
18. Godier A., Parmar K., Manandhar K., Hunt B.J. An in vitro study of the effects of t-PA and tranexamic acid on whole blood coagulation and fibrinolysis. J Clin Pathol. 2017; 70(2): 154-61.
19. Hur W.S., Mazinani N., Lu X.J.D., Britton H.M., Byrnes J.R., Wolberg A.S. et al. Coagulation factor XIIIa is inactivated by plasmin. Blood. 2015; 126(20): 2329-37.
20. Kim P.Y., Stewart R.J., Lipson S.M., Nesheim M.E. The relative kinetics of clotting and lysis provide a biochemical rationale for the correlation between elevated fibrinogen and cardiovascular disease. J Thromb Haemost. 2007; 5(6): 1250-6.
21. Sabate A., Gutierrez R., Beltran J., Mellado P., Blasi A., Acosta F. et al. Impact of Preemptive Fibrinogen Concentrate on Transfusion Requirements in Liver Transplantation: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. Am J Transplant. 2016; 16(8): 2421-9.
22. Hethershaw E.L., Cilia La Corte A.L., Duval C., Ali M., Grant P.J., Ariеns R.A.S. et al. The effect of blood coagulation factor XIII on fibrin clot structure and fibrinolysis. J Thromb Haemost. 2014; 12(2): 197-205.
23. Rijken D.C., Abdul S., Malfliet J.J.M.C., Leebeek F.W.G., Uitte de Willige S. Compaction of fibrin clots reveals the antifibrinolytic effect of factor XIII. J Thromb Haemost. 2016; 14(7): 1453-61.
24. Ichinose A., Japanese Collaborative Research Group on AH13. Autoimmune acquired factor XIII deficiency due to anti-factor XIII/13 antibodies: A summary of 93 patients. Blood Rev. 2017; 31(1): 37-45.
25. Marar T.T., Boffa M.B. Identification of a thrombomodulin interaction site on thrombin-activatable fibrinolysis inhibitor that mediates accelerated activation by thrombin. J Thromb Haemost. 2016; 14(4): 772-83.
Опубликован
2017-12-18
Как цитировать
Будник И. А., Морозова О. Л., Цымбал А. А., Шенкман Б. ., Эйнав Ю. . Влияние концентратов фибриногена, фактора XIII и активируемого тромбином ингибитора фибринолиза на плотность и фибринолитическую устойчивость кровяного сгустка в модели гиперфибринолиза // Патологическая физиология и экспериментальная терапия. 2017. Т. 61. № 4. С. 44–50.
Выпуск
Раздел
Оригинальные исследования
